SION Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Sionna Therapeutics Inc (SION) is not a strong buy for a beginner long-term investor at this moment. While the company has promising developments in cystic fibrosis treatments and positive analyst sentiment, the technical indicators and lack of profitability suggest it may be better to monitor the stock for a more favorable entry point.
The MACD is negative and contracting, RSI is neutral at 34.246, and moving averages are converging, indicating no clear trend. The stock is trading close to its support level at 33.305, with resistance at 38.466. The price change in the regular market is minimal at 0.06%, while pre-market saw a decline of -3.73%.
Analysts have raised price targets recently, with Guggenheim, Citizens, and BTIG providing targets ranging from $50 to $63, citing strong preclinical data and a differentiated approach in cystic fibrosis treatments.
The company has a strong cash position of $310.3 million, expected to sustain operations into
Participation in major healthcare conferences suggests active engagement with the investment and healthcare community.
The company reported a Q4 2025 GAAP EPS of -$0.46, indicating ongoing profitability challenges.
Technical indicators do not show a clear upward trend, and the stock is trading near its support level.
The stock has a 50% chance of declining -5.46% in the next month based on historical patterns.
In Q4 2025, the company reported no revenue growth (0% YoY), a net income loss of -$20.44 million (improved by 28.98% YoY), and an EPS of -0.46 (up 24.32% YoY). While losses have narrowed, the company remains unprofitable.
Analysts are bullish on SION, with multiple Buy or Outperform ratings and price targets ranging from $50 to $63. Analysts highlight the company's potential to revolutionize cystic fibrosis treatment and its strong preclinical data.
